Trial Profile
A Randomized Study of Cetuximab or Cetuximab Plus Docetaxel Followed by Radical Prostatectomy for Patients With Adenocarcinoma of the Prostate.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Docetaxel
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 23 Jun 2009 Planned end date (Aug 2008) added as reported by ClinicalTrials.gov.
- 31 Jul 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 05 May 2007 New trial record.